Squarepoint
RNAC icon

Squarepoint’s Cartesian Therapeutics RNAC Stock Holding History

Squarepoint’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5M Buy
2,254,619
+16,133
+0.7% +$120K 0.03% 619
2026
Q1 		$13.8M Buy
2,238,486
+2,220,273
+12,191% +$15.8M 0.02% 906
2025
Q4 		$131K Buy
+18,213
New +$147K ﹤0.01% 3987
2025
Q1 		– Sell
-10,652
Closed -$191K – 5276
2024
Q4 		$191K Buy
10,652
+259
+2% +$5.24K ﹤0.01% 4488
2024
Q3 		$168K Buy
+10,393
New +$162K ﹤0.01% 3751
2024
Q2 		– Sell
-3,623
Closed -$70.6K – 4553
2024
Q1 		$70.6K Sell
3,623
-2,187
-38% -$46.4K ﹤0.01% 3841
2023
Q4 		$120K Buy
5,810
+4,813
+483% +$144K ﹤0.01% 3723
2023
Q3 		$31.7K Buy
997
+28
+3% +$935 ﹤0.01% 3674
2023
Q2 		$32.5K Sell
969
-2,729
-74% -$97.7K ﹤0.01% 3471
2023
Q1 		$154K Buy
+3,698
New +$174K ﹤0.01% 2881
2022
Q3 		– Sell
-925
Closed -$36K – 3366
2022
Q2 		$36K Buy
+925
New +$27.4K ﹤0.01% 2736
2022
Q1 		– Sell
-505
Closed -$49K – 3412
2021
Q4 		$49K Buy
+505
New +$54.3K ﹤0.01% 3024
2021
Q3 		– Sell
-391
Closed -$49K – 3354
2021
Q2 		$49K Buy
+391
New +$46.6K ﹤0.01% 3107
2021
Q1 		– Sell
-1,341
Closed -$122K – 3538
2020
Q4 		$122K Buy
1,341
+234
+21% +$20.3K ﹤0.01% 2677
2020
Q3 		$82K Buy
+1,107
New +$84.8K ﹤0.01% 2317
2020
Q2 		– Sell
-3,297
Closed -$238K – 2483
2020
Q1 		$238K Buy
+3,297
New +$318K 0.01% 1400

Other funds holding RNAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Squarepoint's RNAC Position: Q2 2026 in Review

Squarepoint increased its Cartesian Therapeutics (RNAC) stake by 0.72% in Q2 2026, buying an estimated $120K and bringing the position to 2,254,619 shares worth $23.5M. The position accounts for 0.03% of the portfolio, ranked #619.

Squarepoint first reported a position in RNAC in Q1 2020 and has held it in 16 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Squarepoint held 2,254,619 shares of Cartesian Therapeutics worth $23.5M as of Q2 2026.
  • Squarepoint bought 16,133 Cartesian Therapeutics shares in Q2 2026, an estimated $120K.
  • Cartesian Therapeutics made up 0.03% of Squarepoint's portfolio in Q2 2026, its #619 holding.
  • Squarepoint first reported a position in Cartesian Therapeutics in Q1 2020 and has held it in 16 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.